US FDA Approves AbbVie's JUVMO for Parkinson's Disease
The US FDA has approved AbbVie’s JUVMO (tavapadon) for Parkinson’s Disease (PD), supported by phase 3 TEMPO data showing improved daily function.
AbbVie JUVMO US FDA Approval | 30/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy